Prix bas
CHF164.00
Pas encore paru. Cet article sera disponible le 01.07.2025
Auteur
Dr. Sharma earned his B. Pharm, M. Pharm and Ph.D. form Pharmaceutical Sciences, Dr. H. S. Gour Central University, Sagar, India. As Assistant Professor, he served in academia at Guru Ramdas Khalsa institute of Science and Technology Jabalpur (M.P.). He has the past experience as Junior research fellow-AICTE, ICMR-SRF and CSIR- research associate during his academic career and currently, working as an assistant manager in biologicals research and development division. He has edited 1 international book Nano Drug Delivery Strategies for the Treatment of Cancers and he published dozens of publications and book chapters. His current research interests are nanocarriers based targeted approach for the effective delivery of bioactives.
Dr. Balak Das Kurmi is working as Associate Professor of Pharmaceutics at ISF college of Pharmacy, Moga, Punjab, INDIA. Previously he was associated at Department of Pharmacy, School of Studies of Natural Resources, Guru Ghasidas Vishwavidyalaya (A-Central University) Bilaspur (C.G.) as a DST-SERB Research fellow and CSIR-Ph.D. Fellow. He has completed B. Pharm and M. Pharm from the Department of Pharmaceutical Sciences, Dr Hari Singh Gour Central University, Sagar, M.P., India. He was awarded DST-SERB/CSIR/ICMR- Fellowship and International Travel Grant from CSIR-New Delhi. He is working on two ICMR Adhoc research Project grants more than 45 lakhs as Co-PI of project. He has expertise in various Novel Drug Delivery Systems such as Liposomes, Nanoparticles, Micelles and Dendrimers.
Dr. Satish Shilpi is currently working in School of Pharmaceutical & Population Health Informatics, DIT University, Dehradun, Uttrakhand. He has completed his bachelor, master and doctorate degree in pharmacy from the Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar, MP, India. He has also worked as Associate Professor and Research Coordinator in AIP, Amity University Madhya Pradesh, Gwalior in year 2022. Dr. Satish has contributed significantly to research on novel and target drug delivery especially nano and microparticles. His research interest in targeted drug delivery to MDR advanced cancer like Triple Negative Breast Cancer, Solid tumor, Lungs and Liver cancer.
Dr. Swarnakar is a seasoned professional with over 15 years of experience in oral and parenteral drug product development. He currently holds the position of North America Application Lab Manager at BASF Corporation, USA. Dr. Swarnakar earned his Ph.D. in Pharmaceutical Science from the National Institute of Pharmaceutical Research and Education in Mohali, India.
Before joining BASF, Dr. Swarnakar served as a Senior Scientist at TesoRx Pharma, USA. He has also held Post-Doctoral positions at the University of Connecticut, the University of Cincinnati, and Western University of Health Science, where he worked on the development of sustained release, controlled release, and enabled drug products.
Dr. Swarnakar is a co-inventor of 10 patents and has authored over 30 publications. His research interests include enhancing the safety and efficacy of difficult-to-deliver drugs, formulation development for bioavailability enhancement, melt extrusion process development for pharmaceutical manufacturing, and continuous manufacturing of lipid-based drug products.
Dr. Awesh K. Yadav has received his B.Pharm, M.Pharm, and PhD from Dr. Hari Singh Gour University Sagar (MP). He is currently working as Assistant Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research Raebareli, India. He has more than 15 years of teaching and industrial experience in various institutes and industries. He has written dozens of quality research publications in journals of national and international repute. He has also published four books and seven book chapters. He has been awarded the best citation award for his publication in the International Journal of Pharmaceutics in 2005. Dr. Yadav's current research interest includes targeted and controlled novel drug delivery systems for the delivery of various bioactives such as anticancer drugs, anti-Alzheimer's drugs, anti-Parkinson drugs, anti-malarial drugs, sun-screening agents, etc.
Texte du rabat
Emerging Paradigms in Delivery of Therapeutic Agents for the Treatment of Glioblastoma describes the intense research and clinical developments that are required to optimize the available treatment options and the potential side effects to heal brain cancer. The success of this strategy includes the use of validated biomarkers, appropriate patient selection criteria, strategies to prevent adverse events, and the implementation of immunotherapy in multimodal treatment approach. In 18 chapters, this title sets forth the rationales for promising therapies like immunotherapy, including immune checkpoint blockade, chimeric antigen receptor T (CAR T) cell therapy, oncolytic virotherapy, and vaccine therapy.
In addition, the book reviews potential novel agents, the current status of preclinical and clinical trials, and the challenges and future perspectives in glioblastoma immuno-oncology. This book is a valuable resource for health professionals, scientists and researchers, health practitioners, students, and all those who wish to broaden their knowledge in the allied field.
Contenu